Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 44.67 | 17.61 | 2.54 | -23.42 |
Depreciation | -32.57 | -34.28 | -31.05 | -32.72 |
Tax paid | 4.31 | 13.21 | -1.96 | -3.16 |
Working capital | 55.88 | -86.12 | 20.69 | -11.18 |
Other operating items | ||||
Operating | 72.28 | -89.56 | -9.77 | -70.48 |
Capital expenditure | -3.53 | -8.03 | -79.24 | 13.23 |
Free cash flow | 68.74 | -97.6 | -89.01 | -57.25 |
Equity raised | 775.93 | 653.47 | 683.78 | 764.12 |
Investing | 0 | 0 | 0 | -28.6 |
Financing | 86.2 | -72.13 | 15.73 | 92.4 |
Dividends paid | 0 | 0 | 0 | 0 |
Net in cash | 930.88 | 483.73 | 610.5 | 770.66 |
Furthermore, the NPRA's recognition will enable Venus Remedies to capitalise on the expanding global demand for enoxaparin.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice